What is Skye Bioscience?
Skye Bioscience is a pharmaceutical company dedicated to creating novel therapeutic solutions for diseases characterized by inflammation, fibrosis, and metabolic dysregulation. The company focuses on developing proprietary molecules designed to address significant unmet medical needs within these therapeutic areas. Its strategic approach involves leveraging scientific innovation to build a robust pipeline of potential treatments, aiming to improve patient outcomes and establish a strong market presence in the competitive biopharmaceutical landscape.
How much funding has Skye Bioscience raised?
Skye Bioscience has raised a total of $73.8M across 3 funding rounds:
Stock Offering
$16.6M
Share Placement
$7M
Share Placement
$50.3M
Stock Issuance/Offering (2015): $16.6M, investors not publicly disclosed
Share Placement (2020): $7M, investors not publicly disclosed
Share Placement (2024): $50.3M supported by Ally Bridge Group, Driehaus Capital Management, and 5AM Ventures
Key Investors in Skye Bioscience
Ally Bridge Group
Ally Bridge Group is a global healthcare investment management firm specializing in high-impact life science innovation, managing over $6 billion in transactions since its inception in 2013. The firm operates from offices in New York and Hong Kong, focusing on both private equity and public equity strategies across the healthcare sector.
Driehaus Capital Management
Founded in 1982 and headquartered in Chicago, Illinois, Driehaus Capital Management is a company that provides investment management services.
5AM Ventures
Five AM Ventures is a life science focused venture capital firm that backs early stage biotech and health care innovators, partnering closely with founders to shape companies, fund rigorous science and help bring new therapies and technologies to patients.
What's next for Skye Bioscience?
With the recent major strategic investment, Skye Bioscience is poised for an accelerated growth phase. The company is expected to channel these funds into advancing its proprietary molecule development, potentially expanding its research and development capabilities, and preparing for future clinical trials. This significant backing from prominent investors suggests confidence in Skye Bioscience's scientific approach and its potential to disrupt key therapeutic markets. The company's focus on inflammatory, fibrotic, and metabolic conditions aligns with growing healthcare demands, positioning it for future success and potential further financing rounds as it progresses through development milestones.
See full Skye Bioscience company page
